Core Insights - Clearmind Medicine Inc. has announced the publication of an international patent application in collaboration with Yissum Research Development Company, focusing on innovative psychedelic-based compounds for treating mental health disorders and addiction [1][2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to discovering and developing novel psychedelic-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [3] - The company currently holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [4] Collaboration and Innovation - The collaboration with Yissum has produced highly innovative compounds that aim to surpass the limitations of traditional psychedelics, reflecting the company's commitment to advancing safe and effective solutions for mental health and addiction disorders [2] - The patent application is part of an exclusive worldwide licensing agreement with Yissum, allowing Clearmind to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds [2]
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders